Cefpodoxime and Potassium Clavulanate Contract Manufacturing: Key Factors Pharma Companies Should Consider

Introduction: Why Contract Manufacturing for Cephalosporin Combinations Is a Different Conversation

Not all antibiotic tablets are manufactured equal — and cefpodoxime proxetil 200mg + potassium clavulanate 125mg is a formulation that demonstrates this more clearly than most. It combines a moisture-sensitive prodrug that requires specific dissolution conditions for bioavailability with a hygroscopic, chemically reactive beta-lactamase inhibitor that degrades rapidly in the presence of moisture, heat, and light. Put them together in a single film-coated tablet with a 24-month shelf life claim, pack them in a 10×6 Alu-Alu blister for moisture protection, and distribute them across India's humid, temperature-variable supply chain — and you have a formulation that genuinely separates capable CMO partners from commodity tablet fillers.

For pharma brands building or expanding their antibacterial portfolio with a cefpodoxime clavulanate tablet for RTI and related infection indications, this guide covers the key manufacturing quality and capability factors that should anchor your CMO evaluation — beyond the headline checklist of WHO-GMP certification and batch size flexibility.

For clinical context on what this combination treats and why prescribers choose it, see our complete guide on cefpodoxime and potassium clavulanate tablet uses.

Factor 1: The Alu-Alu Blister Requirement — Why It Is Non-Negotiable for This Formulation

The 10×6 Alu-Alu blister is not a premium packaging upgrade for cefpodoxime + potassium clavulanate tablets — it is a stability necessity that flows directly from potassium clavulanate's physical chemistry.

Potassium clavulanate is highly hygroscopic. Even at relative humidity levels well within the range found in Indian ambient conditions (50–80% RH during monsoon months), unprotected clavulanate begins to absorb atmospheric moisture, triggering degradation of the beta-lactam ring that carries its beta-lactamase inhibitory activity. The degradation products — primarily clavulanic acid and ring-opened metabolites — have no clinically relevant beta-lactamase inhibitory activity. A tablet that delivers degraded clavulanate delivers cefpodoxime without protection against the beta-lactamase enzymes it was designed to defeat.

Standard PVC/Aluminium blisters have a measured moisture vapour transmission rate (MVTR) that, while adequate for many solid oral dose forms, is insufficient for clavulanate stability over a 24-month shelf life at Indian ambient storage conditions.

Alu-Alu (cold form aluminium) blisters have a near-zero MVTR — providing hermetic moisture, light, and oxygen barrier protection per tablet cavity. Each tablet is sealed in its own complete moisture barrier from the moment of packing until the patient presses it through the foil.

When evaluating a CMO, confirm:

• Do they operate a validated cold-form Alu-Alu blistering line specifically for beta-lactam and beta-lactamase inhibitor combinations?
• Has the blistering process been validated for seal integrity across the target blister dimensions (10×6)?
• Is the Alu-Alu blistering area environmentally controlled for humidity during the packing operation itself — before the blister seal is formed?

A manufacturer who packs clavulanate-containing tablets in standard PVC/Al blisters, or who operates an Alu-Alu line in an uncontrolled humidity environment, is producing a product whose shelf life is compromised from the moment of packaging.

Factor 2: Humidity Control During Blending and Granulation

Before a tablet even reaches the blistering line, clavulanate's hygroscopicity creates a processing challenge that begins at the powder blending stage.

The blending of cefpodoxime proxetil and potassium clavulanate — along with excipients that optimise flow, compressibility, and dissolution — must occur in a relative humidity-controlled environment, typically maintained below 40% RH during all powder-handling operations. Exceeding this threshold during blending or granulation allows clavulanate to begin absorbing moisture before the tablet is even formed — increasing degradation product formation that will appear in the finished product's related substances profile on HPLC.

Ask prospective manufacturers: What is the validated RH specification for your blending suite? Can you provide batch manufacturing records showing RH was within specification throughout the blending and tablet compression operations for a recent batch?

Factor 3: Cefpodoxime Proxetil Dissolution — The Bioavailability Quality Parameter

Cefpodoxime proxetil is an oral prodrug. It must dissolve in the upper gastrointestinal tract, be absorbed through the intestinal mucosa, and then undergo esterase-mediated conversion to active cefpodoxime in the systemic circulation. The rate and completeness of dissolution from the tablet matrix directly determines how much active cefpodoxime reaches the bloodstream — and therefore whether the tablet delivers its label claim in clinical practice.

The dissolution profile of cefpodoxime proxetil tablets is sensitive to formulation variables including:

• Particle size of the proxetil API (smaller particles dissolve faster)
• Excipient selection in the tablet core (some binders reduce dissolution rate)
• Film coat thickness and porosity (a coat that is too dense retards dissolution onset)
• Compression force during tabletting (over-compression reduces surface area for dissolution)

A capable CMO should be able to provide dissolution data for their cefpodoxime + clavulanate tablet formulation showing:

• % dissolved at 30 minutes using USP Apparatus II (paddle method) in pH 4.5 acetate buffer
• Batch-to-batch consistency in dissolution profile across at least three commercial-scale batches
• Comparison of dissolution profiles at accelerated stability conditions (40°C/75% RH) confirming no dissolution rate reduction with ageing

This data demonstrates that the formulation's bioavailability performance is controlled and consistent — not just that the API is present at label claim at the time of manufacture.

Factor 4: Dual-API HPLC Batch Release — The Complete CoA You Must Request

The Certificate of Analysis (CoA) for each batch of cefpodoxime + potassium clavulanate tablets should include HPLC assay of both active ingredients independently — not a combined assay, and not a single API assay with the other assumed to be within specification.

A complete CoA for this formulation includes:

• Cefpodoxime proxetil assay by HPLC — % of label claim (specification typically 90–110%)
• Potassium clavulanate assay by HPLC — % of label claim (specification typically 90–110%)
• Related substances for both APIs — individual and total degradation product limits
• Dissolution — as described above
• Disintegration time — confirms tablet core integrity
• Hardness and friability — mechanical properties that protect tablets through distribution
• Water content (Karl Fischer) — critical for clavulanate stability monitoring
• Microbial limits — TAMC and TYMC per IP/USP limits for non-sterile oral solid dosage forms

Request a sample CoA from a recent batch before finalising any manufacturing agreement. A CoA that shows only assay and description is a quality management gap — and one that your brand will carry in the market.

Factor 5: ICH-Compliant Stability Programme for 24-Month Shelf Life

A 24-month shelf life claim for cefpodoxime + potassium clavulanate tablets must be supported by stability data conducted per ICH Q1A(R2) guidelines:

• Accelerated stability: 40°C / 75% RH, 6 months — primary indicator of degradation under Indian tropical storage stress
• Intermediate stability: 30°C / 65% RH, 12 months — for products intended for distribution in high-humidity regions
• Long-term (real-time) stability: 25°C / 60% RH or 30°C / 65% RH, 24 months — confirmatory data for the full shelf life claim

For clavulanate specifically, the stability programme must track both the clavulanate assay decline (related substances increase) and the cefpodoxime proxetil related substances profile across all timepoints — because both APIs degrade under stability stress conditions, and the commercial shelf life must reflect the more restrictive of the two degradation profiles.

Manufacturers without real-time stability data covering the full 24 months — or those who offer only accelerated data as a proxy for real-time confirmation — cannot support the shelf life claim your product registration requires. This is a common gap among smaller manufacturers who initiate stability programmes but do not maintain them through the full real-time duration.

Factor 6: Regulatory Documentation for Indian and Export Market Registration

A complete regulatory documentation package for cefpodoxime + potassium clavulanate tablet manufacture for Indian domestic market supply includes:

• Manufacturing licence covering antibiotic tablet manufacture under the Drugs and Cosmetics Act 1940
• WHO-GMP certificate with scope explicitly covering oral antibiotic tablet manufacture
• Process validation report — demonstrating that the manufacturing process consistently produces tablets of defined quality across at least three consecutive commercial-scale batches
• Cleaning validation report — particularly critical in a multi-product antibiotic facility to document cross-contamination risk management between different beta-lactam product families
• Drug Master File (DMF) references for cefpodoxime proxetil API and potassium clavulanate API from qualified API suppliers

For export market registration — including regulated markets in South-East Asia, GCC, and Africa — additional documentation requirements apply:

• Site Master File (SMF) per PIC/S format
• Product-specific stability data at ICH conditions
• Dissolution profile comparisons
• IMPD (Investigational Medicinal Product Dossier) or equivalent dossier components depending on the target market's registration pathway

Confirm that your prospective CMO has previously supported product registration in your target markets — not just that they possess the facility documentation that would theoretically support registration. Experience with the actual regulatory submission process for specific markets is a practical differentiator.

Factor 7: CDMO Service Model — What Third-Party Manufacturing Actually Includes

Third-party and CMO manufacturing for a cephalosporin + clavulanate antibiotic tablet involves considerably more than batch production and delivery. A capable CDMO partner for this formulation should offer:

Private labelling and artwork management: Your brand name on the label, compliant with Schedule P (antibiotic labelling requirements) and Schedule V (Drugs and Cosmetics Act), with mandatory warning text, prescription-only designation, and storage instructions accurately printed. The CMO should either provide artwork development support or work cleanly from brand-supplied artwork files with a defined review and approval cycle.

Batch documentation package: Every delivered batch should include the batch manufacturing record (BMR), batch packing record (BPR), in-process check records, and the signed CoA — delivered as a complete documentation package that your quality team can file and reference for any future regulatory inspection or market complaint investigation.

Minimum order quantity flexibility: For antibiotic tablets where the market launch phase requires smaller initial volumes — and where prescriber sampling and tender-based hospital supply creates variable demand — confirm that the CMO's MOQ is compatible with your first-year supply plan. A CMO whose minimum viable batch size exceeds your initial commercial requirement will either over-supply you (increasing inventory holding cost) or be unable to manufacture at all.

Lead time transparency and supply SLA: Ask for a documented lead time from confirmed purchase order to batch delivery, and a clear statement of what happens if a batch fails release — does the CMO commit to a replacement batch timeline, and is this in the manufacturing agreement?

Factor 8: Antibiotic Facility Segregation and Beta-Lactam Cross-Contamination Controls

Cefpodoxime proxetil is a third-generation cephalosporin — a beta-lactam antibiotic. Its manufacture in a facility that also produces non-beta-lactam antibiotics, or non-antibiotic products, requires documented facility segregation and cross-contamination controls to prevent trace contamination of one product category with another.

For brands with patients who may have beta-lactam allergies, the regulatory and clinical risk of cross-contamination between beta-lactam and non-beta-lactam products in a shared manufacturing facility is a specific quality concern. Ask whether the manufacturer produces cefpodoxime + clavulanate tablets in a dedicated beta-lactam suite with separate air handling, dedicated equipment train, and validated cleaning procedures that prevent transfer of beta-lactam residues to non-beta-lactam production areas or vice versa.

This is not a hypothetical concern — it is a documented quality risk that has resulted in regulatory action against Indian pharmaceutical manufacturers across multiple inspection cycles. A CMO with a clearly documented, validated beta-lactam segregation system eliminates this risk from your product's quality profile.

Manufacturer Evaluation Checklist

Conclusion

Choosing a contract manufacturing partner for cefpodoxime + potassium clavulanate tablets is a decision that determines your brand's clinical credibility, regulatory standing, and supply reliability across the product's commercial life. The eight factors in this guide — from Alu-Alu blistering and humidity-controlled manufacturing through dual-API HPLC release, ICH stability, regulatory documentation, and beta-lactam facility segregation — represent the complete quality and capability framework for a procurement evaluation that protects both your brand and the patients who depend on it.

Delwis Healthcare manufactures cefpodoxime clavulanate tablet for RTI and a range of antibiotic tablets at our WHO-GMP certified Ahmedabad facility — with dedicated Alu-Alu blistering lines, humidity-controlled manufacturing suites, dual-API HPLC batch release, ICH-compliant stability programmes, and complete regulatory documentation support. Our antibacterial range includes both oral antibiotic tablets and parenteral formulations — for brands looking to partner on intravenous antibiotics alongside oral step-down therapies, explore ceftriaxone and tazobactam for injection as a complementary injectable antibiotic option. For paediatric oral antibiotic portfolio extensions, see our cefuroxime axetil dry syrup manufacturer and broader tablet manufacturing capabilities.

This article is written for pharmaceutical industry professionals and B2B procurement teams. It is intended for informational and educational purposes within the pharmaceutical manufacturing and sourcing context.